Farallon Capital Management LLC Has $58.60 Million Stock Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Farallon Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 24.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,498,709 shares of the company's stock after buying an additional 684,391 shares during the quarter. Farallon Capital Management LLC owned 2.65% of Centessa Pharmaceuticals worth $58,603,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Fred Alger Management LLC raised its position in shares of Centessa Pharmaceuticals by 7.3% during the 4th quarter. Fred Alger Management LLC now owns 190,451 shares of the company's stock valued at $3,190,000 after acquiring an additional 12,898 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $5,083,000. Cutter Capital Management LP bought a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $2,464,000. BNP Paribas Financial Markets acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at $162,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at $320,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on CNTA shares. Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an "outperform" rating and a $6.00 target price on the stock. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target on the stock. Guggenheim reissued a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reissued an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Chardan Capital initiated coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a "buy" rating and a $30.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of "Buy" and a consensus price target of $27.00.

Insider Activity

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the completion of the transaction, the chief executive officer now owns 331,017 shares of the company's stock, valued at $5,273,100.81. This represents a 14.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Iqbal J. Hussain sold 2,080 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $14.01, for a total value of $29,140.80. Following the completion of the transaction, the general counsel now directly owns 105,386 shares of the company's stock, valued at approximately $1,476,457.86. This trade represents a 1.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 171,398 shares of company stock valued at $2,697,422. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Stock Down 1.9%

Shares of CNTA traded down $0.24 during trading hours on Wednesday, hitting $12.22. 288,469 shares of the company were exchanged, compared to its average volume of 625,914. The company has a market cap of $1.63 billion, a PE ratio of -7.99 and a beta of 1.53. The firm's 50 day moving average is $13.70 and its 200-day moving average is $15.64. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. On average, equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.